Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect

被引:183
|
作者
Vincent, L
Chen, W
Hong, L
Mirshahi, F
Mishal, Z
Mirshahi-Khorassani, T
Vannier, JP
Soria, J
Soria, C
机构
[1] Lab DIFEMA, UFR Med & Pharm Rouen, F-76183 Rouen, France
[2] Hop St Louis, INSERM, U553, Paris, France
[3] Hotel Dieu, Biochim Lab, Paris, France
[4] Hotel Dieu, EMI 99 12, Paris, France
关键词
anti-angiogenesis; migration; HMG-CoA reductase inhibitor; cerivastatin; RhoA; Ras;
D O I
10.1016/S0014-5793(01)02337-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recent studies have suggested that inhibitors of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (statins) can play a role in protection against vascular risk, which is independent of cholesterol reduction. It could act by inhibiting the synthesis of isoprenoids (farnesylpyrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP)), which are respectively essential for membrane attachment and biological activity of GTPases Ras and RhoA. This study demonstrates that a statin (cerivastatin) inhibits angiogenesis, This effect was due to a decrease in endothelial cell locomotion which was reversed by GGPP, It was mainly related to delocalization of RhoA from cell membrane to cytoplasm, responsible for the disorganization of actin stress fibers. Furthermore, a decrease in MMP-2 secretion, involved in cell invasion, mas also observed. This effect is rather due to Ras inhibition as it was reversed by FPP, This antiangiogenic activity could explain the beneficial effect of statins on atherosclerosis and on cancer prevention as shown by clinical studies. (C) 2001 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
引用
收藏
页码:159 / 166
页数:8
相关论文
共 50 条
  • [1] Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin
    Muck, W
    Ritter, W
    Ochmann, K
    Unger, S
    Ahr, G
    Wingender, W
    Kuhlmann, J
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1997, 35 (06) : 255 - 260
  • [2] Biopharmaceutical profile of cerivastatin:: a novel HMG-CoA reductase inhibitor
    Mück, W
    Ochmann, K
    Mazzu, A
    Lettieri, J
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 1999, 27 (03) : 107 - 114
  • [3] Cerivastatin, a novel HMG-CoA reductase inhibitor: Efficacy and tolerability
    Schmage, N
    Cagatay, M
    Park, SM
    Lommerzheim, A
    Schopen, U
    HERZ KREISLAUF, 2000, 32 (7-8): : 242 - 252
  • [4] Cerivastatin (BAY w 6228):: A novel HMG-CoA reductase inhibitor
    Kuhlmann, J
    Mück, W
    Bischoff, H
    von Keutz, E
    Llewellyn, M
    CARDIOVASCULAR DRUG REVIEWS, 1998, 16 (03): : 236 - 263
  • [5] The HMG-CoA reductase inhibitor cerivastatin enhances the nitric oxide bioavailability of the endothelium
    Berkels, R
    Nouri, SK
    Taubert, D
    Bartels, H
    Roesen, P
    Roesen, R
    Klaus, WF
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2003, 42 (03) : 356 - 363
  • [6] Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228) on migration, proliferation and cholesterol synthesis in arterial myocytes
    Corsini, A
    Arnaboldi, L
    Raiteri, M
    Quarato, P
    Faggiotto, A
    Paoletti, R
    Fumagalli, R
    PHARMACOLOGICAL RESEARCH, 1996, 33 (01) : 55 - 61
  • [7] HMG-CoA reductase inhibitor improves endothelial dysfunction in mineralocorticoid hypertension by inhibition of RhoA
    Hermann, M
    Ruschitzka, F
    Camici, G
    Shaw, S
    Luscher, TF
    AMERICAN JOURNAL OF HYPERTENSION, 2003, 16 (05) : 24A - 24A
  • [8] Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells
    Denoyelle, C
    Albanese, P
    Uzan, G
    Hong, L
    Vannier, JP
    Soria, J
    Soria, C
    CELLULAR SIGNALLING, 2003, 15 (03) : 327 - 338
  • [9] Mechanism of preventive effect of HMG-CoA reductase inhibitor on diabetic nephropathy
    Yokota, T
    Utsunomiya, K
    Murakawa, Y
    Kurata, H
    Tajima, N
    KIDNEY INTERNATIONAL, 1999, 56 : S178 - S181
  • [10] Biphasic effect of HMG-CoA reductase inhibitor, pitavastatin, on vascular endothelial cells and angiogenesis
    Katsumoto, M
    Shingu, T
    Kuwashima, R
    Nakata, A
    Nomura, S
    Chayama, K
    CIRCULATION JOURNAL, 2005, 69 (12) : 1547 - 1555